23.1 Which of the following drugs is a nondepolarizing neuromuscular blocker:
A. Succinylcholine
B. Vecuronium
C. Decamethonium
D. Dantrolene sodium
23.2 The site of action of d-tubocurarine is:
A. Spinal internuncial neurone
B. Motor nerve ending
C. Muscle end-plate
D. Sodium channels in the muscle fibre
23.3 At the muscle end-plate, d-tubocurarine reduces the:
A. Number of Na+ channels
B. Duration for which the Na+ channels remain open
C. Ion conductance of the open Na+ channel
D. Frequency of Na+ channel opening
23.4 Depolarizing neuromuscular blockers differ from competitive
blockers in the following attributes except:
A. They induce contraction of isolated frog rectus abdominis muscle
B. Ether anaesthesia intensifies block produced by them
C. Tetanic nerve stimulation during partial
depolarizing block produces well sustained
contraction
D. Neostigmine does not reverse block produced by them
23.5 Succinylcholine produces spastic paralysis in:
A. Rabbits
B. Frogs
C. Birds
D. Patients with atypical pseudocholinesterase
23.6 The fall in blood pressure caused by d-tubocurarine is due to:
A. Reduced venous return
B. Ganglionic blockade
C. Histamine release
D. All of the above
23.7 Select the skeletal muscle relaxant that is commonly
used for endotracheal intubation despite causing
histamine release, K+ efflux from muscles and
cardiovascular changes:
A. Pipecuroniun
B. Succinylcholine
C. Pancuronium
D. Cisatracurium
23.8 Neuromuscular blocking drugs do not produce central actions because:
A. They do not cross the blood-brain barrier
B. Nicotinic receptors are not present in the brain
C. They are sequestrated in the periphery by tight binding to the skeletal muscles
D. They do not ionise at the brain pH
23.9 Pancuronium differs from tubocurarine in that:
A. It is a depolarizing blocker
B. Its action is not reversed by neostigmine
C. It can cause rise in BP on rapid I.V. injection
D. It causes marked histamine release
23.10 Which of the following drugs undergoes ‘Hofmann’ elimination:
A. Succinylcholine
B. Pancuronium
C. Vecuronium
D. Atracurium
23.11 The neuromuscular blocker that does not need
reversal of action by neostigmine at the end of the
operation is:
A. d-Tubocurarine
B. Doxacurium
C. Pipecuronium
D. Mivacurium
23.12 The most rapidly acting nondepolarizing neuromuscular
blocking agent which can be used as an alternative
to succinylcholine for tracheal intubation is:
A. Rocuronium
B. Pancuronium
C. Doxacurium
D. Pipecuronium
23.13 Succinylcholine is the preferred muscle relaxant for tracheal intubation because:
A. It produces rapid and complete paralysis of respiratory muscles with quick recovery
B. It does not alter heart rate or blood pressure
C. It does not cause histamine release
D. It does not produce postoperative muscle soreness
23.14 Which of the following is applicable to mivacurium:
A. It undergoes Hoffmann elimination
B. It is the shortest acting nondepolarizing neuromuscular blocker
C. It is excreted unchanged by kidney
D. It does not cause histamine release
23.15 Neostigmine reverses the following actions of d-tubocurarine except:
A. Motor weakness
B. Ganglionic blockade
C. Histamine release
D. Respiratory paralysis
23.16 Postoperative muscle soreness may be a side effect of the following neuromuscular blocker:
A. d-tubocurarine
B. Succinylcholine
C. Pancuronium
D. Atracurium
23.17 The following antibiotic accentuates the nuromuscular blockade produced by pancuronium:
A. Streptomycin
B. Erythromycin
C. Penicillin G
D. Chloramphenicol
23.18 Dantrolene sodium reduces skeletal muscle tone by:
A. Reducing acetylcholine release from motor nerve endings
B. Suppressing spinal polysynaptic reflexes
C. Inhibiting the generation of muscle action potential
D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre
23.19 Which of the following is a centrally acting skeletal muscle relaxant:
A. Carisoprodol
B. Dantrolene sodium
C. Quinine
D. Decamethonium
23.20 Select the muscle relaxant that is used to control
spasticity associated with upper motor neurone
paralysis:
A. Vecuronium
B. Succinylcholine
C. Chlorzoxazone
D. Baclofen
23.21 The GABAB receptor:
A. Is an intrinsic ion channel containing receptor
B. Mediates neuronal depolarization
C. Is insensitive to blockade by bicuculline
D. Regulates intracellular cAMP
23.22 The following is a skeletal muscle relaxant that acts
as a central α2 adrenergic agonist:
A. Tizanidine
B. Brimonidine
C. Chlormezanone
D. Quinine
23.23 Which of the following is not true of tizanidine:
A. It is a clonidine congener used in spasticity
due to stroke or spinal injury
B. It reduces muscle tone by activating GABAB receptors
C. It inhibits release of excitatory amino-acids in spinal interneurones
D. It reduces muscle spasms without producing weakness
23.24 Diazepam is used as a muscle relaxant for:
A. Deep intra-abdominal operation
B. Tracheal intubation
C. Tetanus
D. Diagnosis of myasthenia gravis
23.25 Indications of centrally acting muscle relaxants
include all of the following except:
A. Balanced anaesthesia
B. Traumatic muscle spasms
C. Torticollis
D. Electroconvulsive therapy
Ans:
23.1 B 23.2 C 23.3D 23.4 B 23.5 C 23.6 D 23.7 B 23.8 A 23.9 C 23.10D 23.11D 23.12 A 23.13 A 23.14 B 23.15 C 23.16 B 23.17 A 23.18D 23.19 A 23.20D 23.21 C 23.22A 23.23 B 23.24 C 23.25 A
Thank you for sharing knowledge
ReplyDeleteE-pharmacy market in India